Biopharmaceutical company GSK plc (LSE/NYSE: GSK) announced on Wednesday that the European Commission has approved a fully liquid version of Menveo, its meningococcal Group A, C, W-135, and Y conjugate vaccine (MenACWY).
This single-vial formulation, which eliminates the need for reconstitution, simplifies immunisation against invasive meningococcal disease (IMD) and is approved for individuals aged two years and older.
The approval follows two Phase IIb trials demonstrating comparable immunogenicity, tolerability and safety to the existing lyophilised/liquid version. This new presentation supports efficient vaccination workflows for a disease known for its severe, life-threatening complications. IMD remains a critical global health concern, with high mortality rates and significant long-term effects for survivors.
The original lyophilised Menveo formulation, approved in 2010, remains available. Menveo is authorised in over 60 countries and has delivered over 82 million doses globally, with more than 6 million distributed in Europe since 2017.
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma
FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid